Supplementary Appendix II: "Handoff improvement and adverse events-reduction program implementation in paediatric intensive care units in Argentina: a stepped-wedge trial"

Figure 1. Study sample in stepped wedge cluster randomized trial, showing health records reviewed in each cluster and period.

PICUs					Mon	th of the	study				
Ficos	Jul-18	Aug-18	Sep-18	Oct-18	Nov-18	Dec-18	Jan-19	Feb-19	Mar-19	Apr-19	May-19
1	27	21	15	18	10	13	22	8	11	14	14
2	30	29	24	17	12	12	14	16	12	15	24
3	12	16	13	14	25	22	15	13	14	18	17
4	30	30	30	30	30	30	30	30	30	30	29
5	30	30	30	30	30	30	30	30	30	30	29
6	27	24	27	24	24	21	17	21	18	17	30

☐ Control

□Intervention

Table 1. Preventable adverse event per site and per period.

	Rates for 1000 days (95%	•	Rate of rates (Intervention/Control)	p-Value*
Site	Intervention	Control	(95% CI)	•
1	27.6 (20.8;36.7)	37.4 (29.5;47.4)	0.74 (0.51;1.07)	0.109
2	21.3 (14.2;32.1)	32.2 (23.3;44.4)	0.66 (0.39;1.11)	0.122
3	84.5 (66.1;108.0)	84.4 (65.7;108.3)	1.00 (0.71;1.42)	0.995
4	82.7 (65.4;104.5)	73.5 (61.8;87.4)	1.12 (0.84;1.51)	0.430
5	112.8 (87.9;144.6)	139.8 (106.2;184)	0.81 (0.56;1.17)	0.257
6	42.2 (28.6;62.2)	28.9 (15.8;52.8)	1.46 (0.71;2.98)	0.304

^{*}p-value was obtained from the generalized mixed linear model adjusted by the time effect.

Table 2: Total amount of adverse event and preventable adverse event by type and group

	Adverse	events	Non preventa	
	Intervention (N=698)	Control (N=767)	Intervention (N=698)	Control (N=767)
Health-care-associated infections				
Central line-associated blood stream	11	19	10	19
infection				
Sepsis/bacteremia unrelated to catheter	18	30	17	30
Ventilator-associated pneumonia	59	57	59	56
Nosocomial pneumonia, not ventilator-	8	13	5	8
related				
Catheter-associated UTI	43	74	43	74
Hospital-acquired viral illness	11	17	10	17
Surgical site infection	9	3	9	2
Endometritis	0	0	0	0
C. difficile colitis	2	1	2	1
Respiratory				
Acute respiratory failure (RR elevated or	19	17	16	14
depressed))				
Respiratory distress, not acute failure	2	0	0	0
Pneumothorax/hemothorax/SQ air	12	15	11	13
Barotrauma	3	0	3	0
Atelectasis (CXR findings with increased [A-a]	11	5	7	4
O ₂ gradient)				
Bronchospasm	0	2	0	0
Aspiration (witnessed, with or without CXR	1	1	1	1
changes)				
Pulmonary Embolus	0	0	0	0
Post extubation stridor	13	22	2	3
R mainstem bronchus intubation	1	1	1	1
Unplanned extubation	0	0	0	0
Reintubation within 24 hrs of planned	23	18	23	18
extubation				
Other Respiratory (note: ventilator-	35	37	7	9
associated pneumonia and other pneumonia				
is under infections section)				
Gastrointestinal				
Nausea / vomiting	0	1	0	0
Diarrhea	0	1	0	1
Constipation	6	2	4	2
Gastric distension	0	0	0	0
Pancreatitis	0	0	0	0

Jaundice / hepatic insult (elevated bilirubin /	9	4	0	0
elevated ALT and/or AST)				
Ileus	0	2	0	2
Other GI	1	4	1	3
Surgical / Obstetrical				
Post-operative hemorrhage	8	6	3	4
Post-operative hematoma	2	0	1	0
Laceration or other injury of organ	0	2	0	1
Unplanned removal of organ due to intra-	0	0	0	0
operative injury				
Vascular injury	1	2	0	0
Nerve injury	0	0	0	0
Surgical anastomosis failure	0	1	0	1
Wound dehiscence	4	5	1	1
Retained foreign instrument or sponge	0	0	0	0
Failed procedure (e.g., need for revision)	5	3	5	0
Unplanned return to surgery	8	3	5	0
Uterine rupture	0	0	0	0
Major placental abruption	0	0	0	0
Unplanned / emergency hysterectomy	0	0	0	0
Fetal / neonatal complications associated	0	0	0	0
with delivery (e.g. stillbirth, birth trauma,				
dystocia, unplanned NICU admission)				
Other surgical or obstetrical	10	5	2	4
Renal/Fluids/Endocrine				
Fluid overload (new CHF, severe edema or increased [A-a] O ₂ gradient associated with IV	6	4	6	4
fluids)				
Dehydration / Oliguria (urine output <0.5cc/kg TBW > 4 hrs; or CVP < 5 or PAWP < 8 with signs of dehydration)	0	0	0	0
Acute renal failure (increased Creat > 50%	12	16	6	8
with or without oliguria)			_	-
Metabolic acidosis (HCO ₃ < 20)	1	2	0	1
Metabolic alkalosis (HCO ₃ > 30)	0	1	0	1
Adrenal insufficiency (Low baseline or ACTH	0	0	0	0
stimulation test cortisol and / or responds to				
corticosteroid Rx)				
Hyperglycemia	3	4	1	4
Hypoglycemia	7	14	7	10
Hyperkalemia	1	1	0	1
Other Renal / Fluids / Endocrine	13	13	10	8
Neurologic				

Our and debies (days and et all)	2		2	-
Oversedation (drug related)	2	8	2	6
Delirium / Encephalopathy	0	5	0	1
Seizures	6	3	3	2
CVA / Intracerebral hemorrhage	0	1	0	1
Paralysis / Neuromuscular blocker excess	0	0	0	0
Obtundation (not drug-related)	13	1	13	1
Inadequate sedation/anxiolysis	0	0	0	0
Inadequate analgesia	0	0	0	0
Withdrawal symptoms	17	17	13	15
Other neurologic	6	7	2	5
Cardiovascular				
Cardiac Arrest	31	23	8	15
Hypotension	9	10	3	5
Hypertension	4	2	4	1
Low cardiac output	4	1	4	1
Shock (non-cardiogenic) (hypotension and	5	3	4	1
oliguria or altered sensorium or peripheral				
hypoperfusion)				
Arrhythmias / Conduction abnormality (new	5	13	3	5
VT, VF, AF, SVT, bradycardia or heart block)				
Myocardial infarction/ischemia (ECG changes	0	0	0	0
and/or increased troponin or CK-MB)				
Pulmonary edema (Increased [A-a] O ₂	0	3	0	3
gradient or new CXR clinical findings or				
PCWP≥18				
Peripheral (extremity) ischemia (absent	0	3	0	1
pulses or skin color and temperature				
changes)				
Other cardiovascular	6	0	4	0
Hematologic				
Hemorrhage (Hct ↓ > 5% or needs RBC	28	22	17	15
transfusions)			_,	-5
Thromboembolic event - venous	9	21	4	16
Thromboembolic event - arterial	3	3	0	1
Hematoma	2	2	2	2
Other Hematologic, Specify	9	9	6	5
Other Categories				
Hypothermia (Temperature < 35° C)	2	5	0	5
Pyrexia (Temperature > 39° C)	0	0	0	0
Alcohol or drug withdrawal	8	6	7	3
Allergic reaction (e.g. rash, hives, anaphylaxis)	3	5	1	2
Fall	0	0	0	0
Pressure Ulcer	10	19		19
FIESSUIE UILEI	10	19	10	

Death	21	9	5	2
Rash (non-allergic)	1	0	0	0
Line complication	41	38	37	36
Tube complication (chest tube, foley, etc.)	6	4	6	4
Other harm type not listed above	37	37	26	31

Table 3. Proportion of compliance on the key elements of verbal handoffs in each site

Verbal Site	Illness severity		Patient su	mmary	Action	list	Situation awa contingen		Synthesis by t	he receiver
	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control
1	81.7%	0.0%	93.3%	10.5%	63.3%	4.0%	10.0%	0.0%	93.3%	2.6%
2	73.8%	4.0%	100.0%	81.6%	96.7%	36.8%	16.4%	9.2%	62.3%	0.0%
3	65.4%	0.0%	99.0%	65.5%	81.2%	0.0%	53.5%	0.0%	85.2%	0.0%
4	83.3%	0.0%	93.8%	61.9%	83.3%	22.6%	58.3%	4.8%	95.8%	36.9%
5	83.8%	34.7%	100.0%	91.7%	36.3%	12.5%	2.5%	1.4%	90.0%	0.0%
6	73.7%	63.3%	96.8%	90.0%	95.8%	83.3%	99.0%	73.3%	67.4%	46.7%

Table 4. Proportion of compliance on the key elements of written handoffs in each site

Written Site	Illness severity		Illness severity Patient summary Action list		Situation awareness and contingency plans		Synthesis by the receiver			
	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control	Intervention	Control
1	98.3%	0.0%	95.0%	1.3%	68.3%	15.8%	10.0%	0.0%	96.7%	1.3%
2	98.4%	1.3%	100.0%	61.8%	45.9%	7.9%	37.7%	1.3%	16.4%	0.0%
3	93.1%	1.7%	97.0%	46.6%	93.1%	13.8%	71.3%	0.0%	88.1%	0.0%
4	95.8%	0.0%	100.0%	86.9%	91.7%	10.7%	83.3%	0.0%	95.8%	0.0%
5	86.1%	0.0%	88.6%	0.0%	13.9%	0.0%	1.3%	0.0%	8.7	0.0%
6	82.1%	20.0%	87.4%	60.0%	92.6%	73.3%	94.7%	70.0%	66.3%	16.7%